Emrullah Yilmaz

Nov 1, 2024 | jitc.bmj.com | Alan Ho |Lisle M Nabell |Prakash Neupane |Emrullah Yilmaz

AbstractBackground Only a minority of patients (20%) with Human Papillomavirus (HPV) 16-positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) responds to first-line (1L) monotherapy with pembrolizumab, and no approved therapies exist targeting HPV+ disease specifically. Eseba-vec (previously known as HB-200) utilizes arenavirus vectors to induce potent HPV-16 E6 and E7-specific CD8 T-cell responses.